Changchun High-Tech Industry (SHE:000661) unit Bcht Biotechnology's application of a recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation was accepted by China's drug regulator.
The drug is intended to prevent lower respiratory tract infections in newborns and infants, according to a Wednesday filing with the Shenzhen bourse.